Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

H. Lee Moffitt Cancer Center and Research Institute, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Support Through Remote Observation and Nutrition Guidance Program for Individuals With Gastroesophageal Cancer

Not Applicable

Recruiting

Conditions: GastroEsophageal Cancer

Interventions: Behavioral: Dietitian Consultation
Behavioral: Survey
Behavioral: Fitbit Data Collection
Behavioral: Referral to Dietitian
Behavioral: Social Determinants of Health Survey (SDOH)

First Posted Date: 2024-07-11

Last Posted Date: 2025-06-19

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 80

Registration Number: NCT06497569

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

Mindfulness-Based Ecological Momentary Intervention For Smoking Cessation Among Cancer Survivors

Phase 1

Active, not recruiting

Conditions: Any Cancer Type

Interventions: Behavioral: EMI

First Posted Date: 2024-06-26

Last Posted Date: 2025-03-17

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 12

Registration Number: NCT06476548

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG)

Phase 1

Withdrawn

Conditions: Recurrent High-grade Glioma

Interventions: Drug: Xevinapant

First Posted Date: 2024-06-17

Last Posted Date: 2024-12-04

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 12

Registration Number: NCT06463184

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy

Early Phase 1

Recruiting

Conditions: Breast Cancer
Triple Negative Breast Cancer

Interventions: Procedure: Leukapheresis
Biological: Dendritic Cell (DC) Vaccine

First Posted Date: 2024-05-30

Last Posted Date: 2025-06-18

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 16

Registration Number: NCT06435351

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Exercise Prehabilitation for Locoregional Esophageal Cancer

Not Applicable

Recruiting

Conditions: Esophageal Cancer

Interventions: Behavioral: Exercise

First Posted Date: 2024-05-28

Last Posted Date: 2025-05-07

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 20

Registration Number: NCT06430346

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Generating Novel Translational and Therapeutic Strategies Based on a Multicenter, Pediatric and AYA Evolutionary Tumor Board (pedsETB)

Recruiting

Conditions: Pediatric Cancer

Interventions: Other: Peds Evolutionary Tumor Board (pedsETB)

First Posted Date: 2024-05-21

Last Posted Date: 2025-04-18

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 35

Registration Number: NCT06423950

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer

Not Applicable

Recruiting

Conditions: Pancreatic Cancer

Interventions: Behavioral: Physical Activity
Behavioral: Nutrition Counseling
Behavioral: Resistance Training

First Posted Date: 2024-05-21

Last Posted Date: 2025-06-25

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 26

Registration Number: NCT06423963

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Early Phase 1

Recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: Taxotere
Drug: Cytoxan
Drug: Trastuzumab deruxtecan
Drug: Sacituzumab govitecan
Drug: Xeloda
Drug: Fulvestrant
Drug: Ribociclib
Drug: Abemaciclib

First Posted Date: 2024-05-10

Last Posted Date: 2025-05-06

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 15

Registration Number: NCT06409390

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer

Phase 1

Recruiting

Conditions: Pancreatic Cancer
Locally Advanced Pancreatic Cancer

Interventions: Drug: Pembrolizumab
Device: Irreversible Electroporation

First Posted Date: 2024-04-22

Last Posted Date: 2025-04-18

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 3

Registration Number: NCT06378047

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

Phase 2

Recruiting

Conditions: Follicular Lymphoma
Marginal Zone Lymphoma
B-Cell Lymphoma

Interventions: Drug: Zanubrutinib
Drug: Rituximab

First Posted Date: 2024-04-05

Last Posted Date: 2025-04-17

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 43

Registration Number: NCT06350318

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy